EVOLUT R TRANSCATHETER AORTIC VALVE
Report
- Report Number
- 2025587-2017-00265
- Event Type
- Injury
- Date Received
- February 20, 2017
- Date of Event
- November 1, 2016
- Report Date
- January 27, 2017
- Manufacturer
- MEDTRONIC HEART VALVES DIVISION
- Product Code
- NPT
- PMA / PMN Number
- P130021
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- AS
- Reporter Occupation
- PHYSICIAN
Narratives
CITATION: MEREDITH I ET AL. LONGEST FOLLOW-UP AFTER IMPLANTATION OF A SELF-EXPANDING REPOSITIONABLE TRANSCATHETER AORTIC VALVE. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. NOVEMBER 2016: 68(18): B302-B303. DOI: 10.1016/J.JACC.2016.09.162. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.
MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REVIEW REGARDING FOLLOW-UP AFTER TRANSCATHETER AORTIC VALVE IMPLANT. ALL DATA WERE COLLECTED FROM MULTIPLE CENTERS. THE STUDY POPULATION INCLUDED 60 PATIENTS (PREDOMINANTLY FEMALE; MEAN AGE 83 YEARS), ALL OF WHICH WERE IMPLANTED WITH MEDTRONIC EVOLUTR BIOPROSTHETIC VALVE (SERIAL NUMBERS NOT PROVIDED). AMONG ALL PATIENTS FOUR DEATHS OCCURRED; NONE OF THE DEATHS WERE ATTRIBUTED TO MEDTRONIC PRODUCT. AMONG ALL PATIENTS ADVERSE EVENTS INCLUDED: TWO DISABLING STROKE, TWO MODERATE PARAVALVULAR LEAK, AND 9 PERMANENT PACEMAKER IMPLANTS. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 126061 | EVOLUT R TRANSCATHETER AORTIC VALVE | AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED | NPT | MEDTRONIC HEART VALVES DIVISION | EVOLUTR-23 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 83 YR | Required Intervention |